Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-10-01 18:32:28 - browse：7

The ability of cancer cells to move and spread depends on actin-rich core structures such as the podosomes (yellow) shown here in melanoma cells. Cell nuclei (blue), actin (red), and an actin regulator (green) are also shown. — Metastatic melanoma cells Julio C. Valencia,/NCI Center for Cancer Research

Nearly four decades after its first conception, the first TIL therapy, an immunotherapy that harvests cancer-fighting immune cells from the patient’s own body, received accelerated approval from the Food and Drug Administration for advanced melanoma. The therapy, called Amtagvi or lifileucel from Iovance, is the first cell therapy approved for a solid tumor.

“It’s so exciting and gratifying,” said Allison Betof Warner, a cell therapy researcher and physician at Stanford University who has worked on Amtagvi. “This is a game-changing moment for our field. We’ve seen huge success of cellular therapy for hematologic malignancies, and we’ve yet to capitalize on that for solid tumors. This is hopefully the first of many to come.”

In a Phase 2 clinical trial, titled C-144-01, 153 patients who had already been on a median of three prior lines of therapy received lifileucel, and 31% of them responded to therapy. “These are in very late line patients. They’ve exhausted every standard care option,” Betof Warner said. “The most promising part of this therapy for me is that 42% of patients who responded were still responding for 18 months or longer. It’s truly incredible.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Citing H5N1 threat, CDC urges peak flu monitoring this summer

focus

leisure time

knowledge

WSS

Listen: More tumult at BIO & coercive care for sickle cell patients

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Precocious puberty in girls comes with mental health risks

First medicine developed to treat MASH expected to be approved soon

Cue Health, Covid

Amylyx ALS drug failure raises questions and concerns

explore

Wikipedia

focus

United colonoscopy coverage change 'may cost lives,' doctors say

Fentanyl is making it harder to start addiction treatment

As demand for Covid shots wanes, Moderna seeks its next success

Amylyx ALS drug failure raises questions and concerns

Activists slam private health insurers over coverage restrictions

Making the case for fair compensation in clinical trials

Anesthesiologist group: stop taking Ozempic before surgery

Amylyx ALS drug fails large clinical trial

Hepatitis C has a cure — but many Americans still lack access to it

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

hotspot

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Listen: More tumult at BIO & coercive care for sickle cell patients

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Change Healthcare cyberattack prompts Medicare loan program

ASCO eve: Let’s set the table for this year's meeting

focus

leisure time

knowledge

leisure time